J. Peto, J. Hodgson, M. Fe, and J. Jones, Continuing increase in mesothelioma mortality in Britain, The Lancet, vol.345, issue.8949, pp.535-544, 19954.
DOI : 10.1016/S0140-6736(95)90462-X

A. Banaei, B. Auvert, and M. Goldberg, Future trends in mortality of French men from mesothelioma, Occupational and Environmental Medicine, vol.57, issue.7, pp.488-94, 2000.
DOI : 10.1136/oem.57.7.488

P. Grosclaude, A. Guizard, E. Imbernon, B. Lapôtre-ledoux, K. Ligier et al., Evolution of pleural 601 cancers and malignant pleural mesothelioma incidence in France between, Int J 602 Cancer, vol.126, issue.1, pp.232-240, 1980.

F. Galateau-sallé, A. Gislard, M. Letourneux, A. Luc, E. Schorlé et al., Pleural plaques and the risk 605 of pleural mesothelioma, J Natl Cancer Inst Feb, vol.20105, issue.4, pp.293-301, 2013.

G. Soit-ilg, A. Imbernon, E. , L. Stang, N. Pairon et al., Occupations and 608 industries in France at high risk for pleural mesothelioma: a population-based case-control study, Am J Ind Med, vol.60953, issue.12, pp.1207-1226, 1998.

G. Soit-ilg, A. Imbernon, E. , L. Stang, N. Pairon et al., 612 Attributable risk in men in two French case-control studies on mesothelioma and asbestos, Eur J 613 Epidemiol, 0614.

G. Soit-ilg, A. Goldeeg, M. , P. Chaigs, S. Ducamps et al., Programme national de 615 surveillance du mésothéliome ? Principaux résultats 1998-2006. Saint-Maurice (Fra) : Institut de 616 veille sanitaire, 2009.

C. Gramond, E. Imbernon, R. P. Pairon, and J. , Compensation of pleural mesothelioma in France: 21

M. Goldberg, E. Imbernon, R. P. , G. Soit-ilg, A. Savès et al., The French National Mesothelioma Surveillance Program, Occupational and Environmental Medicine, vol.63, issue.6, pp.390-395, 2006.
DOI : 10.1136/oem.2005.023200

. Monography, Pathology of malignant mesothelioma; An update of the International 626

A. Marchevsky, A. Nicholson, V. Roggli, W. Travis, and M. Wick, Guidelines for Pathologic Diagnosis of 630 Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International 631 Mesothelioma Interest Group, Arch Pathol Lab Med, vol.632, issue.12, p.633, 2012.

F. Salle, A. Gibbs, A. Gown, S. Hammar, L. Litzky et al., Guidelines for 634 pathologic diagnosis of malignant mesothelioma: a consensus statement from the International 635 Mesothelioma Interest Group, Arch Pathol Lab Med, vol.133, issue.8, pp.1317-1348, 2009.

F. Penault-llorca, Recommendations and quality control in immunohistochemistry, Ann Pathol

P. Brochard, H. Begueret, J. Vignaud, K. Kerr, G. Launoy et al., 648 Lymphohistiocytoid variant of malignant mesothelioma of the pleura: A series of 22 cases, Am J, p.649

P. Brochard, Which criteria for the anatomopathologic diagnosis of malignant pleural 652 mesothelioma?]. Rev Mal Respir, pp.11-37, 2006.

F. Galateau-sallé, J. Vignaud, L. Burke, A. Gibbs, E. Brambilla et al., Mesopath group. Well-differentiated papillary mesothelioma of the pleura: a series of 24 cases, p.655

D. Waller and R. Rami-porta, International Association for the Study of Lung Cancer International 658 Staging Committee and the International Mesothelioma Interest Group. Recommendations for 659 uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus 660 report of the international association for the study of lung cancer international staging 661 committee and the international mesothelioma interest group, J Thorac Oncol, 2011.

P. Hofman, A. Cazes, P. Andujar, S. Imbeaud, F. Petel et al., Molecular classification of malignant pleural mesothelioma: Identification ofa poor 666 prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clinical Cancer Research 667 accepté. 668 21

F. Demirag, H. Zeren, R. Attanoos, A. Gibbs, P. Cagle et al., Prognostic significance of 670 p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch, pp.627-662, 2008.

P. Cagle, R. Attanoos, A. Gibbs, F. Galateau-salle, and H. Popper, EGFR and PDGFR differentially 673 promote growth in malignant epithelioid mesothelioma of short and long term survivors, Thorax, vol.67463, issue.4, pp.345-51, 2008.

D. Jean, J. Daubriac, L. Pimpec-barthes, F. Galateau-salle, F. Jaurand et al., Molecular changes in 676 mesothelioma with an impact on prognosis and treatment, Arch Pathol Lab Med, 2012.

N. Weinbreck, J. Vignaud, H. Begueret, L. Burke, J. Benhattar et al., SYT-SSX fusion is absent in sarcomatoid mesothelioma allowing its distinction from synovial sarcoma of the pleura, Modern Pathology, vol.14, issue.6, pp.617-638, 2007.
DOI : 10.1038/modpathol.3800775

G. Zalcman and F. Galateau-sallé, Plasma cell membrane localization of c-MET predicts longer survival 683 in patients with malignant mesothelioma: a series of 157 cases from the MESOPATH Group, J, vol.684

M. Letourneux, I. Monnet, J. Régnard, P. Validire, J. Zucman-rossi et al., Differential 688 mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and 689 pleural mesothelioma, Mutagenesis, 2013.